Stock Screener App

무료 - Play StoreApp Store

설치하다 설치하다

Dow:

Nasdaq:

S&P 500:

GALT

$3.325.68%-0.20

Galectin Therapeutics Inc (GALT)

Date: O: H: L: C: Vol:

Galectin Therapeutics Inc 주식(GALT)의 최신 뉴스

Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - What's Next? - MarketBeat

Galectin Therapeutics Inc. Estimates – NASDAQ:GALT - TradingView

MarketBeat cites USD 11.00 target for Galectin Therapeutics stock - AD HOC NEWS

Galectin Therapeutics stock has November 13 earnings, USD -0.05 estimate - ad-hoc-news.de

Galectin Therapeutics (GALT) Slips 1.35% to $3.66 as Shares Sit Between Key Levels - Call Dominated - https://www.siam.in/

Galectin Therapeutics (NASDAQ:GALT) Stock Price Breaks Above 200 Day Moving Average - Here's Why - MarketBeat

GALECTIN THERAPEUTICS INC SEC Filing (Oct 13, 2026) - Stock Titan

Galectin Therapeutics Reports Fiscal Year 2025 10-K Highlighting Belapectin Clinical Progress - Kalkine Media

Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above Two Hundred Day Moving Average - Here's Why - MarketBeat

Galectin Therapeutics stock gets a Phase 3 protocol update - AD HOC NEWS

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 - The Manila Times

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026 - Yahoo Finance

Galectin: $105M Debt Conversion Clears The Balance Sheet, But Phase 3 Partnership Is Critical - Seeking Alpha

Galectin Therapeutics seeks 250 million shares: what it means for Galectin Therapeutics stock - ad-hoc-news.de

Galectin Therapeutics (NASDAQ:GALT) Stock Price Crosses Above Two Hundred Day Moving Average - Time to Sell? - MarketBeat

Galectin Therapeutics stock falls 2.22 percent as trial advances - AD HOC NEWS

Galectin Therapeutics stock holds a $399.36 million valuation - AD HOC NEWS

Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above Two Hundred Day Moving Average - Here's What Happened - MarketBeat

Galectin Therapeutics stock holds steady as investors await next clinical updates - AD HOC NEWS

Galectin Therapeutics stock holds recent gains after phase 2b trial update - AD HOC NEWS

Galectin Therapeutics Inc. (GALT) Key Financial Ratios – Valuation, Profitability & More - Value Research

Galectin Therapeutics at H.C. Wainwright: belapectin nears phase III - Investing.com

Why Is Galectin Therapeutics (NASDAQ:GALT) Breaking Out Now? - Kalkine Media

Galectin Therapeutics (NASDAQ:GALT) Stock Crosses Above 200-Day Moving Average - Here's Why - MarketBeat

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times

A drug company will present in New York Sept. 14. Galectin will meet investors there. - Stock Titan

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Yahoo Finance

Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times

Galectin Therapeutics Stock Price Forecast. Should You Buy GALT? - StockInvest.us

Galectin Therapeutics (NASDAQ:GALT): Can Momentum Outrun Weak Results? - Kalkine Media

Galectin Therapeutics (NASDAQ:GALT) Shares Pass Above Two Hundred Day Moving Average - What's Next? - MarketBeat

Galectin Therapeutics Inc. (GALT) Peer Comparison – Compare with Others - Value Research

Galectin Therapeutics Inc. (GALT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research

Galectin Therapeutics (NASDAQ:GALT): Is Momentum Turning Stronger? - Kalkine Media

Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving Average - Here's What Happened - MarketBeat

Bronstein, Gewirtz & Grossman, LLC Encourages Galectin Therapeuti - The National Law Review

Galectin (GALT) Q1 2026 Earnings: The EPS Result Is Below Expectation for the Current Session; Share Move - vinanet.vn

Galectin (GALT) Today: Posts a 5.43% Gain to $3.88 in the Current Update; Technical Setup: the Price Remains Bounded by the Supplied Support and Resistance on the Day - Triple MA Cross - vinanet.vn

Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight - PR Newswire UK

Galectin (GALT) EPS and Revenue: EPS Misses Its Estimate; Trading Move: The Stock Loses 0.63% in the Available Record - Upward Estimate Revision - vinanet.vn

Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response - vinanet.vn

HC Wainwright Analysts Lift Earnings Estimates for GALT - MarketBeat

Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in Focus - SuperTrend Flip - vinanet.vn

Galectin Therapeutics (GALT) Holds Gains at $3.49 After 1.45% Advance — Key Levels in Focus - Chart Pattern Alerts - dars.gov.et

H.C. Wainwright Maintains Galectin Therapeutics(GALT.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Form 8K Galectin Therapeutics Inc For: 14 August By Investing.com - Investing.com Nigeria

Galectin Therapeutics (NASDAQ:GALT) Issues Quarterly Earnings Results - MarketBeat

Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Galectin Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Galectin Therapeutics Q2 Results: EPS misses estimate, losses widen - scanx.trade

GALT와(과) 유사한 종목

NVCT$18.480.48%

ZVRA$10.280.77%